Virtu Financial LLC Invests $107,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Virtu Financial LLC acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,046 shares of the biopharmaceutical company’s stock, valued at approximately $107,000.

A number of other hedge funds have also made changes to their positions in the stock. OLD Second National Bank of Aurora acquired a new stake in Amicus Therapeutics in the third quarter worth approximately $26,000. Hazlett Burt & Watson Inc. raised its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI bought a new position in Amicus Therapeutics during the third quarter valued at about $32,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Amicus Therapeutics during the third quarter worth about $55,000.

Amicus Therapeutics Price Performance

FOLD opened at $9.73 on Friday. The firm has a market capitalization of $2.91 billion, a P/E ratio of -28.62 and a beta of 0.60. The stock has a fifty day moving average of $10.49 and a 200-day moving average of $10.61. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57.

Insider Buying and Selling

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 30,401 shares of company stock valued at $339,363. Corporate insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

FOLD has been the subject of a number of research analyst reports. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.